Price History
Feb 9, 2026 — Jul 6, 2026Investment Snapshot
- Trading 162% above Graham Number — above intrinsic value estimate
- Piotroski F-Score 4/9 — moderate financial health
- Strong ROE of 33.2% with 28.7% net margin
- Revenue growing at 6% annually
Johnson & Johnson Common Stock (JNJ) is a Healthcare company operating in Pharmaceutical Preparations, listed on the NYSE , with a market capitalisation of $580.1 billion . Key value metrics: P/E ratio 21.5, P/B ratio 7.15, Piotroski F-Score 4 out of 9 (moderate financial health) .
Value Score
Key Metrics
Current vs 5-Year Average
Based on 5 years of SEC filingsRevenue & Net Income
Financial Statements
| Metric | FY22 | FY23 | FY24 |
|---|---|---|---|
| Revenue | $X.XB | $X.XB | $X.XB |
| Gross Profit | $X.XB | $X.XB | $X.XB |
| Operating Income | $X.XB | $X.XB | $X.XB |
| Net Income | $X.XB | $X.XB | $X.XB |
| EBITDA | $X.XB | $X.XB | $X.XB |
| Total Assets | $X.XB | $X.XB | $X.XB |
| Total Liabilities | $X.XB | $X.XB | $X.XB |
Johnson & Johnson Common Stock — Fundamental Analysis Summary
Johnson & Johnson Common Stock (JNJ) is currently trading 162% above its Graham Number of $92.13, suggesting the market price exceeds Benjamin Graham's intrinsic value estimate. The stock carries an elevated trailing P/E ratio of 21.5x.
On financial health, JNJ shows a moderate Piotroski F-Score of 4/9, and strong return on equity of 33.2% (sector average: -20.6%), and manageable leverage with a debt-to-equity ratio of 0.68.
StockPik's composite Value Score for JNJ is 65/100 — an above-average value rating. The score is built from ten fundamental signals: P/E, P/B, PEG ratio, P/S ratio, return on equity, gross margin, debt-to-equity, current ratio, dividend yield, and Piotroski F-Score.
JNJ shows revenue growing at 6% year-over-year, with earnings growing at 91%.
JNJ pays a modest dividend yield of 2.1%.